Related Experiment Video
Updated: May 17, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?
1Department of Haematology, Manchester Royal Infirmary, Oxford Road, Manchester, UK. jeckothachil@yahoo.co.uk
Low molecular weight heparin is used in the treatment of patients with antiphospholipid syndrome, who develop thrombosis while being managed on oral anticoagulants. Although laboratory monitoring of this agent is not widely performed, it has been suggested to be useful in selected situations of high-risk thrombosis and bleeding. It is however not entirely clear, whether the dose should be altered on the basis of anti-Xa results in asymptomatic individuals.
Low molecular weight heparin is used in the treatment of patients with antiphospholipid syndrome, who develop thrombosis while being managed on oral anticoagulants. Although laboratory monitoring of this agent is not widely performed, it has been suggested to be useful in selected situations of high-risk thrombosis and bleeding. It is however not entirely clear, whether the dose should be altered on the basis of anti-Xa results in asymptomatic individuals.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Dosage Regimen: Multiple Oral Dosage

